Cure of Disseminated Human Lymphoma with [(177)Lu]Lu-Ofatumumab in a Preclinical Model

Although immunotherapies that target CD20 on most non-Hodgkin lymphoma (NHL) cells have improved patient outcomes, current therapies are inadequate because many cases are, or become, refractory or undergo relapse. Here, we labelled the third-generation human anti-CD20 antibody ofatumumab with (177)L...

Descripción completa

Detalles Bibliográficos
Autores principales: Shim, Kyuhwan, Longtine, Mark S., Abou, Diane S., Hoegger, Mark J., Laforest, Richard S., Thorek, Daniel L.J., Wahl, Richard L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Society of Nuclear Medicine 2023
Materias:
Featured Basic Science Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10071784/
https://www.ncbi.nlm.nih.gov/pubmed/36357179
http://dx.doi.org/10.2967/jnumed.122.264816

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10071784/
https://www.ncbi.nlm.nih.gov/pubmed/36357179
http://dx.doi.org/10.2967/jnumed.122.264816

Ejemplares similares